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Abstract
Background: Chronic kidney disease (CKD) is associated with an increased risk of fracture. Decreased bone mass
and disruption of microarchitecture occur early in the course of CKD and worsens with the progressive decline in
renal function so that at the time of initiation of dialysis at least 50% of patients have had a fracture. Despite the
excess fracture risk, and the associated increases in morbidity and mortality, little is known about the factors that
are associated with an increase in fracture risk. Our study aims to identify prognostic factors for bone loss and
fractures in patients with stages 3 to 5 CKD.
Methods: This prospective study aims to enroll two hundred and sixty men and women with stages 3 to 5 CKD.
Subjects will be followed for 24 months and we will examine the ability of: 1) bone mineral density by dual x-ray
absorptiometry at the spine, hip, and radius; 2) volumetric bone density by high resolution peripheral quantitated
computed tomography at the radius and tibia; 3) serum markers of bone turnover; 4) bone formation rate by bone
biopsy; and 5) muscle strength and balance to predict spine and non-spine fractures, identified by self-report and/
or vertebral morphometry. All measurements will be obtained at baseline, at 12 and at 24 months with the
exception of bone biopsy, which will be measured once at 12 months. Subjects will be contacted every 4 months
to determine if there have been incident fractures or falls.
Discussion: This study is one of the first that aims to identify risk factors for fracture in early stage CKD patients.
Ultimately, by identifying risk factors for fracture and targeting treatments in this group-before the initiation of
renal replacement therapy - we will reduce the burden of disease due to fractures among patients with CKD.
Background
Chronic kidney disease (CKD) affects 5-10% of the
world population [1] and is associated with many
adverse outcomes including bone disorders and frac-
tures. Osteoporosis is characterized by a reduction in
bone mass and disruption of skeletal microarchitecture
leading to an increased susceptibility to fracture with
minimal trauma. Decreased bone mass and disruption of
microarchitecture occur early in the course of CKD and
worsens with the progressive decline in renal function
so that at the time of initiation of dialysis at least
50% of patients have had a fracture [2-5]. After a hip
fracture, the average length of stay in an acute care
hospital is 3 weeks; 25% of patients must remain in
long-term care institutions for at least one year, and a
third who return home must depend on other people or
devices for mobility [6].
The prevalence of osteoporotic hip and vertebral frac-
tures among dialysis patients exceeds that of the general
population, with profound effects on morbidity and
mortality [4,5,7-11]. A recent retrospective study [12]
reported that the incidence of hip fractures in a hemo-
dialysis population was 17.4 times greater and occurred
at a younger age compared to the general population
(16 and 13 years younger among men and women,
respectively). Furthermore, patients with CKD stage 5
who require renal replacement therapy (also known as
end stage renal disease (ESRD)) had a one-year mortality
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to 20% in the general population.
The first step to decreasing the morbidity and mortal-
ity associated with fractures in patients with CKD is to
identify those patients at high risk, in order to direct
appropriate preventative strategies. While most research
has focused on identifying prognostic factors for fracture
among ESRD patients, it excludes the earlier stages of
CKD and also has several pragmatic limitations. For
example, dialysis patients are frequently reluctant to
participate in studies due to the required additional time
commitments outside of regularly scheduled dialysis ses-
sions. As well, assessments may be invasive, and may
not have direct patient benefit. As a result, most bone
related studies in ESRD involve a select population com-
prising small numbers of relatively young, healthy
patients, with limited clinical assessments [7,8,13-18].
This limits the generalizability of these studies. Finally,
because of differences in mineral metabolism with
decreasing renal function, the risk factors for fracture in
patients with ESRD may not be the same as the risk fac-
tors for fracture in patients with earlier stages of CKD.
The etiology of fractures in patients with CKD is mul-
tifactorial. Factors that may play a role include decreases
i nt h eq u a n t i t yo fb o n eo ro s t e o p o r o s i sw h i c hc a nb e
identified by bone mineral density (BMD) testing, and
alterations in the quality of bone. Bone quality can be
indirectly assessed by markers of bone turnover and per-
ipheral quantitated computed tomography (pQCT) and
directly assessed with bone biopsy. Other risk factors for
fracture in patients with CKD may be poor nutrition,
inactivity, and an increased risk of falling due to myopa-
thy and peripheral neuropathy [19]. As a result, there
are no recommendations or standard methods of prac-
tice to assess fracture risk. Indeed most clinicians caring
for patients with CKD do not utilize BMD testing, mea-
surement of bone turnover markers, pQCT or bone
biopsy to assess fracture risk. Bone biopsy, in particular,
is not used in clinical practice to assess fracture risk.
Further, those clinicians who do order the occasional
noninvasive test to assess fracture risk in patients with
CKD may not know how to confidently interpret the
results. The FRACTURE study (Fracture Risk Assess-
ment in Chronic Kidney Disease, Prospective Testing
Under Real World Environments) has been designed to
expand the current knowledge of prognostic factors for
fracture in ESRD to the CKD stage 3 to 5 population
and address some of the existing knowledge gaps in the
identification, diagnosis, and interpretation of bone
disease and fracture risk in CKD.
Study Aim
The aim of this study is to prospectively identify prog-
nostic factors for bone loss and fractures in patients
with stages 3 to 5 CKD.
Study Hypotheses
We will test four primary hypotheses in patients with
CKD stages 3-5:
1. BMD at cortical sites (the mid radius) will be asso-
ciated with fractures.
2. Volumetric BMD at the forearm by High Resolu-
tion-pQCT (HR-pQCT) will be associated with
fractures.
3. There will be a positive correlation between the
neuromuscular testing (i.e., the timed up and go) and
presence of fractures.
4. There will be a positive association between frac-
tures and the presence of either: adynamic bone disease,
or hyperparathyroid bone disease, as defined by the
bone formation rate (BFR).
Methods
Study Design and Setting
This is a 24-month prospective cohort study of 260 men
and women attending outpatient renal clinics at the
University Health Network (UHN), and at St. Michael’s
Hospital in Toronto, Ontario, Canada. Other sites will
be recruited as necessary. Subjects will undergo all test-
ing (described below) upon study entry and then at 12
and 24 months with the exception of bone biopsy,
which will be performed only once at 12 months. Sub-
jects who progress to ESRD will have assessments at the
time of dialysis initiation or transplantation, and then
12 months later. Subjects will also be contacted by tele-
p h o n ee v e r y4m o n t h s ,a tw h i c ht i m et h e yw i l lb ea s k e d
about the occurrence of falls and fractures since their
last study contact.
Table 1 Stages of Chronic Kidney Disease [14]
Stage Description Glomerular Filtration Rate (GFR); mL/min/1.73 m
2
1 Kidney damage with normal or increased GFR ≥90
2 Kidney damage with mild decrease in GFR 60 to 89
3 Moderate decrease in GFR 30 to 59
4 Severe decrease in GFR 15 to 29
5 Kidney Failure <15 or dialysis
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This study has been reviewed by the local Research
Ethics Boards, and has received ethics approval at all
participating institutions.
Eligibility
I n c l u s i o nC r i t e r i a :M e na n dw o m e na g e d1 8y e a r sa n d
older, with a glomerular filtration rate of ≤60 mL/min/
1.73 m
2 at study entry are eligible for recruitment.
Exclusion Criteria: Patients who are unable to give
informed consent, unable to have spinal radiographs or
BMD measurements; those taking bisphosphonates, cal-
citonin, hormone replacement therapy, or the oral con-
traceptive pill are excluded. Subjects allergic to
tetracycline are excluded from the bone biopsy compo-
nent of the study.
Predictor Variables
All assessments (below), with the exception of bone
biopsy, will be obtained at a single site (UHN) using
standard protocols.
i. Bone Mineral Density
BMD will be measured at the lumbar spine (L1 to L4),
the total hip, femoral neck and proximal radius using a
bone densitometer (Hologic). To reduce variability,
BMD will be measured using a standard protocol
(including regular use of a phantom spine). BMD tests
will be reported according to the International Society
for Clinical Densitometry (ISCD) protocol by a single
ISCD certified clinician blinded to the study hypotheses.
ii. High Resolution Peripheral Quantitative Computed
Tomography
HR-pQCT measurements will be obtained at the non-
dominant radius (non-weight bearing site), and also at
the tibia (weight bearing site) using the Xtreme CT
device (Scanco Medical AG, Basserdorf, Switzerland).
Measurements that can be obtained from HR-pQCT
include: total volumetric density, cortical volumetric
density, trabecular volumetric density, cortical thickness,
trabecular thickness, trabecular separation, and trabecu-
lar number. The reproducibility of density measure-
ments is <0.3% CV (phantom) [20].
iii. Markers of Bone Turnover
Blood samples will be collected, and then centrifuged at
4°C for 15 minutes. Serum will be aliquotted and imme-
diately stored in microtubes at -80°C for future mea-
surement of bone turnover markers and bone cytokines.
iv. Bone biopsy
Bone histomorphometry will be performed in a sub-
group of 50 subjects. To ensure adequate power, 25 sub-
jects with confirmed prevalent fractures will be included,
as well as 25 without confirmed fracture. We will obtain
a bone biopsy of the anterior superior iliac crest at
12 month follow up only.
Tetracycline labeling:
Subjects will be given tetracycline labels administered
over ~2 week period as follows: Two days of tetracycline
(250 mg, by mouth, four times per day), and then given
a 12 day intermission (days 3-14). On day 15, subjects
will be given the same tetracycline (250 mg, by mouth,
four times per day) for 4 days (days 15-18). Anterior
iliac crest bone biopsies will be obtained one to two
days later. By labeling twice with tetracycline standard
histomorphometry can determine the mineral apposition
rate and mineralizing perimeter for the two separate
labeling periods and thereby calculate the BFR.
Bone biopsy technique:
The iliac biopsy will be obtained following the proto-
col of Meunier [21], using a Bordier trephine, 8 mm in
internal diameter, to avoid fracture and compression of
the core of bone and minimize sampling error. The pro-
cedure is performed under local anesthesia, supplemen-
ted by parenteral sedation if needed to achieve proper
muscle relaxation.
Samples will be processed at 4°C according to standar-
dized techniques. The primary histomorphometric vari-
able to be studied is the BFR. The classification of bone
disease associated with ESRD is based on the BFR and it
has been purported that either an increased BFR (e.g.
>500 μm/mm tissue area/day; as seen in hyperparathyr-
oidism) or a decreased BFR (e.g. <108 μm/mm tissue
area/day; as seen in adynamic bone disease), may be the
strongest predictor of fractures. We will determine if
the BFR is a prognostic factor for fracture by first classi-
fying turnover into low, normal or high, based on the
reference values noted above.
v. Muscle Strength, Balance and Falls
Muscle strength and balance will be assessed using three
tests: The Timed Up and Go (TUG), Hand Grip, and in
a subgroup of subjects, the 6-Minute Walk Test (6MW).
These tests allow determination of muscle strength and
balance across a wide range of functional abilities, has
been validated in populations with renal disease and has
been shown to be associated with fractures in cross sec-
tional studies of patients with ESRD [3].
Primary Outcome Variable
i. Spine and Nonspine Fractures
Subjects will be questioned about a history of non-spine
fractures at baseline and every 4 months during the fol-
low up. Fractures will be classified as either traumatic or
“low trauma” (osteoporotic) based on World Health
Organization criteria; an osteoporotic fracture is defined
as a fracture from one’s standing height or less. Data
from a prospective study demonstrate that self-report of
fractures is accurate for osteoporotic fractures [22]. Sub-
jects will have anterior and lateral radiographs of the
thoracic and lumbar spine at study entry to evaluate the
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then at 12 and 24 months to assess the development of
new (incident) vertebral fractures. All radiographs will
be obtained and reviewed using a standardized metho-
dology, vertebral morphometry [23], by a muscular-
skeletal radiologist with expertise in the radiographic
diagnosis of vertebral fractures.
Withdrawal from Study
If requested, subjects will be withdrawn from the study
without prejudice, as documented and explained at the
time of consenting.
Statistical Considerations
i. Sample Size Estimations
Based on our prior experience with recruiting subjects
with ESRD, and the natural history of CKD the study
anticipates recruitment of 260 subjects over 2 years. It is
estimated that of these 260 subjects, 60 will have renal
transplants, progress to ESRD or die, leaving 200 sub-
jects. The power calculations were based on compari-
sons of mean baseline values between 30% of patients
with prevalent fractures and 70% without prevalent frac-
tures. This 30% is a conservative estimate given prior
data that demonstrates that 50% of CKD patients have
sustained a fracture prior to starting dialysis [2-5], and
data from the Canadian Multicentre Osteoporosis Study
demonstrates that among a population based sample of
healthy men and women 50 years and older 38% of men
a n d4 1 %o fw o m e nh a v eh a daf r a c t u r e[ 2 4 ] .As a m p l e
size of 200 subjects is adequate to meet all our hypoth-
eses. Sample size calculations for each of the primary
hypotheses are detailed below:
1. BMD at cortical sites (the mid radius) will be asso-
ciated with fractures Based on a review of the litera-
ture, a well accepted minimal clinically important
difference (MCID) in BMD between fractured and non-
fractured patients is 3%, which is associated with stan-
dard deviations (SD) that range from 4.5% to 6.8%
[25-32]. We will have 81% (at a SD of 6.8%) to 99%
power (at a SD of 4.5%) to detect a 3% difference in mid
radius BMD.
2. Volumetric BMD at the forearm by HR-pQCT will
be associated with fractures The limited published data
suggest that an MCID in volumetric BMD ranges from
1 to 3 with a SD that varies from 1 to 2 [20]. The most
conservative assumption is a MCID of 1 with an SD 2.
We will have 89% power to detect this MCID.
3. There will be a positive correlation between the
“TUG” and presence of fractures Our data demon-
strates a MCID of 5 seconds that can be associated with
a SD of 10 to 12 seconds. We will have 89 to 76%
power to detect this difference.
4. There will be a positive association between frac-
tures and the presence of either: adynamic bone dis-
ease, or hyperparathyroid bone disease, as defined by
the BFR Power calculations for this hypothesis were
based on the assumption that of the 60 patients with
prevalent fractures (30% of 200) just under half (40%)
would agree to biopsy (25 subjects) and we would
recruit another 25 non-fractured subjects for a total of
50. If we assume that 85% of patients with fracture
would have an abnormal BFR, we have 80% power to
detect an abnormal BFR rate of 45% or lower in the
non-fractured group. We anticipate that approximately
45% of subjects will have incident fractures in the two-
year follow-up period.
ii. Statistical Analyses
We will use linear regression models to assess relation-
ships, with BMD, volumetric BMD (by HR-pQCT),
TUG and BFR (from bone biopsy) as predictor variables
and presence or absence of prevalent fracture as the
main outcome variable. Unadjusted analyses will be per-
formed to determine the association between each pre-
dictor variable of interest and fracture outcome. Those
with a positive association will be adjusted for poten-
tially confounding covariates such as gender, age,
weight, serum calcium, diabetes, and intact serum PTH.
Goodness-of-fit will be evaluated for all models by
inspecting plots of residuals, as well as use of Hosmer
and Lemeshow Goodness of fit test; variables will be
transformed as necessary. Our primary analyses will not
be stratified by gender as earlier work by our group has
not demonstrated a significant difference in fractures by
gender among patients with renal disease. However sup-
plementary analyses will be performed separately by
gender and by the presence of type II diabetes. We will
consider a p value of less than 0.05 statistically signifi-
cant and we will not adjust for multiple comparisons.
Our study statistician will perform our analyses using
STATA version 10 (STATA Corp. College Stn. TX) and
R 2.7 (R Development Core Team (2008). R: A language
and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria)
Anticipated Challenges and Solutions
We have anticipated some potential challenges and have
offered corresponding solutions:
1. Subjects drop out after enrollment
Based on chart review of the Renal Management Clinic
at the UHN, approximately 15 to 20% of subjects pro-
gress to ESRD, receive a transplant, transfer care or die
every year, with very few patients lost to follow up. To
account for these potential “drop outs” after enrollment,
we will recruit 260 subjects, in anticipation that 200 will
continue to be followed.
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The clinic at UHN has a potential pool of over 500 sub-
jects, however, we have established collaborative links
with St. Michael’s Hospital in Toronto as well as with
other Toronto area institutions, which will assist us in
recruiting and meeting our sample size goals.
3. Failure to obtain adequate samples for bone biopsy
component
It is possible, due to the invasive nature of the bone
biopsy procedure that few patients will consent. To
maximize the number of biopsies and to limit drop
outs, the protocol was designed so that we obtain a sin-
gle bone biopsy at one year follow up, rather than
obtaining repeat bone biopsy samples. Note that there is
a paucity of data on bone histomorphometry and stages
of CKD - thus at a minimum our findings will serve as
pilot data for a larger study.
Discussion
This study is designed to identify risk factors for frac-
ture in early stage CKD patients. To our knowledge, no
other prospective studies in Canada have been con-
ducted to determine fracture risk factors in patients
with stage 3-5 CKD, not yet on renal replacement ther-
apy. Ultimately, by identifying risk factors for fracture
and targeting treatments in this group - before initiating
renal replacement therapy - we will reduce the burden
of disease due to fractures among patients with ESRD.
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